RHJA
IOVA icon

Rice Hall James & Associates’s Iovance Biotherapeutics IOVA Stock Holding History

Rice Hall James & Associates’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.41M Buy
1,539,840
+24,933
+2% +$94.7K 0.31% 83
2026
Q1 		$5.32M Buy
1,514,907
+89,819
+6% +$287K 0.3% 79
2025
Q4 		$3.89M Sell
1,425,088
-26,284
-2% -$60.8K 0.21% 109
2025
Q3 		$3.15M Sell
1,451,372
-140,203
-9% -$331K 0.17% 120
2025
Q2 		$2.74M Buy
1,591,575
+22,363
+1% +$55.6K 0.15% 136
2025
Q1 		$5.23M Sell
1,569,212
-25,320
-2% -$131K 0.31% 73
2024
Q4 		$11.8M Sell
1,594,532
-84,625
-5% -$784K 0.65% 46
2024
Q3 		$15.8M Buy
1,679,157
+43,132
+3% +$409K 0.85% 31
2024
Q2 		$13.1M Sell
1,636,025
-77,800
-5% -$834K 0.79% 36
2024
Q1 		$25.4M Sell
1,713,825
-37,082
-2% -$432K 1.45% 17
2023
Q4 		$14.2M Buy
1,750,907
+28,196
+2% +$148K 0.82% 38
2023
Q3 		$7.84M Sell
1,722,711
-36,048
-2% -$235K 0.5% 54
2023
Q2 		$12.4M Buy
1,758,759
+28,795
+2% +$206K 0.7% 45
2023
Q1 		$10.6M Sell
1,729,964
-92,116
-5% -$636K 0.6% 46
2022
Q4 		$11.6M Buy
1,822,080
+388,024
+27% +$3.03M 0.67% 42
2022
Q3 		$13.7M Sell
1,434,056
-267,135
-16% -$3.08M 0.8% 40
2022
Q2 		$18.8M Buy
1,701,191
+616,070
+57% +$8.07M 0.91% 34
2022
Q1 		$18.1M Buy
1,085,121
+453,337
+72% +$7.01M 0.72% 43
2021
Q4 		$12.1M Sell
631,784
-230,163
-27% -$5.07M 0.43% 56
2021
Q3 		$21.3M Sell
861,947
-21,448
-2% -$505K 0.79% 43
2021
Q2 		$23M Buy
883,395
+177,468
+25% +$4.61M 0.82% 40
2021
Q1 		$22.4M Sell
705,927
-5,471
-0.8% -$227K 0.73% 44
2020
Q4 		$33M Sell
711,398
-28,472
-4% -$1.13M 1.16% 30
2020
Q3 		$24.4M Buy
739,870
+59,933
+9% +$1.84M 0.98% 33
2020
Q2 		$18.7M Buy
679,937
+227,595
+50% +$7.48M 0.8% 38
2020
Q1 		$13.5M Buy
+452,342
New +$12M 0.76% 43

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Rice Hall James & Associates's IOVA Position: Q2 2026 in Review

Rice Hall James & Associates increased its Iovance Biotherapeutics (IOVA) stake by 1.6% in Q2 2026, buying an estimated $94.7K and bringing the position to 1,539,840 shares worth $6.41M. The position accounts for 0.31% of the portfolio, ranked #83.

Rice Hall James & Associates first reported a position in IOVA in Q1 2020 and has held it in 26 quarters since. The position peaked at $33M in Q4 2020. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Rice Hall James & Associates held 1,539,840 shares of Iovance Biotherapeutics worth $6.41M as of Q2 2026.
  • Rice Hall James & Associates bought 24,933 Iovance Biotherapeutics shares in Q2 2026, an estimated $94.7K.
  • Iovance Biotherapeutics made up 0.31% of Rice Hall James & Associates's portfolio in Q2 2026, its #83 holding.
  • Rice Hall James & Associates first reported a position in Iovance Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • Rice Hall James & Associates's Iovance Biotherapeutics position peaked at $33M in Q4 2020.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.